Cargando…

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

BACKGROUND: In this prospective phase 2 trial, we assessed the efficacy of trastuzumab-emtansine (T-DM1) in HER2-negative metastatic breast cancer (MBC) patients with HER2-positive CTC. METHODS: Main inclusion criteria for screening were as follows: women with HER2-negative MBC treated with ≥ 2 prio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jacot, William, Cottu, Paul, Berger, Frederique, Dubot, Coraline, Venat-Bouvet, Laurence, Lortholary, Alain, Bourgeois, Hugues, Bollet, Marc, Servent, Veronique, Luporsi, Elisabeth, Espié, Marc, Guiu, Severine, D’Hondt, Veronique, Dieras, Veronique, Sablin, Marie-Paule, Brain, Etienne, Neffati, Souhir, Pierga, Jean-Yves, Bidard, Francois-Clement
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854749/ https://www.ncbi.nlm.nih.gov/pubmed/31727113 http://dx.doi.org/10.1186/s13058-019-1215-z

Ejemplares similares

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
por: Cabel, Luc, et al.
Publicado: (2021)

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma
por: Daveau, C, et al.
Publicado: (2014)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months’ Remission with Lapatinib plus Capecitabine
por: Mailliez, Audrey, et al.
Publicado: (2014)

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
por: Cabel, Luc, et al.
Publicado: (2020)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis
por: Paracha, Noman, et al.
Publicado: (2020)

Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?
por: Alexandre, Marie, et al.
Publicado: (2019)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2013)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
por: Darrigues, Lauren, et al.
Publicado: (2021)

Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
por: Vincent-Salomon, A, et al.
Publicado: (2007)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
por: Chalumeau, Clelia, et al.
Publicado: (2022)

HER2 Oncogenic Function Escapes EGFR Tyrosine Kinase Inhibitors via Activation of Alternative HER Receptors in Breast Cancer Cells
por: Kong, Anthony, et al.
Publicado: (2008)

Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice
por: Ladjemi, Maha Z, et al.
Publicado: (2011)

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Comparison of HER2 and Phospho-HER2 Expression between Biopsy and Resected Breast Cancer Specimens Using a Quantitative Assessment Method
por: Bai, Yalai, et al.
Publicado: (2013)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial
por: Diéras, Véronique, et al.
Publicado: (2019)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
por: Porte, B., et al.
Publicado: (2020)

HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
por: Agostinetto, Elisa, et al.
Publicado: (2021)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer
por: Diéras, Véronique, et al.
Publicado: (2018)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients
por: Jobard, Elodie, et al.
Publicado: (2017)

Quantification of HER1, HER2 and HER3 by time-resolved Förster resonance energy transfer in FFPE triple-negative breast cancer samples
por: Ho-Pun-Cheung, Alexandre, et al.
Publicado: (2019)

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
por: Lanotte, Romain, et al.
Publicado: (2020)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
por: Wege, Anja Kathrin, et al.
Publicado: (2020)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model
por: Karlsson, Jenny, et al.
Publicado: (2023)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3976jakl8n4er3g6mn0gdbo3n3